Company: CRVO
Filing Date: 2025-04-18
Form Type: 8-K
Source: 0001437749-25-012337
Chunk: 0

Company: CervoMed Inc.
Filing Date: 2025-04-18
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01

Entry into a Material Definitive Agreement

Executive Vice President, Clinical Development

On April 14, 2025, the Board of Directors (the “ Board”) of CervoMed Inc. (the “ Company,” “we” or “us”) appointed Kelly Blackburn, M. H. A., as the Company’s Executive Vice President, Clinical Development, effective April 16, 2025. Ms. Blackburn has previously served as the Company’s Senior Vice President, Clinical Development, since August 2023. Ms. Blackburn’s biography is set forth in our Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission (the “ SEC”) on April 29, 2024 (the “2024 Proxy Statement”), and is incorporated by reference herein.

In connection with her appointment, the Company and Ms. Blackburn have entered into an Amended and Restated Employment Agreement (the “ Blackburn Employment Agreement”) pursuant to which she will serve as our Executive Vice President, Clinical Development, which is attached hereto as Exhibit 10.1. Ms. Blackburn’s annual base salary for the year ending December 31, 2025, will be $448,360 - which amount the Board may increase (but not decrease) at its discretion - and her target annual bonus will be 35 percent of her base salary. In addition, the Blackburn Employment Agreement contains certain severance and change of control provisions, non-competition and non-solicitation provisions (each applicable during employment and for 12 and 24 months thereafter, respectively), and confidentiality and non-disparagement provisions (each applicable during employment and at all times thereafter), which are described in more detail under the heading “ - Post-Termination Severance and Change in Control Arrangements” in our 2024 Proxy Statement and incorporated by reference herein. The Blackburn Employment Agreement has an indefinite term.

Executive Vice President, Regulatory and Government Affairs and Program Management

On April 14, 2025, the Board appointed Mark De Rosch, Ph. D., FRAPS as Executive Vice President, Regulatory and Government Affairs and Program Management, effective May 1, 2025. Dr. De Rosch has previously served as the Company’s Senior Vice President, Regulatory and Government Affairs and Program Management, since November 2024. Prior to joining the Company, Dr. De Rosch consulted on drug development and global regulatory strategies since May 2023. Previously, Dr. De Rosch was Chief Operating Officer